Beta Drugs Limited (NSEI: BETA)
Health Care · Pharmaceuticals · IN
Rs2,327.70
-8.74% today · +21.3% 1Y
Beta Drugs Limited (NSEI: BETA) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $245.58M.
Over the last twelve months the share price has gained 21.3%, trading between 990.10 and 2.81K.
Tweenvest scores Beta Drugs Limited across four factors: quality 81/100, value 28/100, growth 79/100. Its strongest factor is quality.
BETA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $245.58M
- Revenue (TTM)
- $43.38M
- P/E
- 52.53
- EPS
- 44.31
- Dividend yield
- —
- Beta (5Y)
- -0.45
- 52-week high
- Rs2,807.90
- 52-week low
- Rs990.10
- Avg volume (3M)
- —
- Shares outstanding
- 10.09M
- Employees
- —
- Next earnings
- —
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,255.40 | +0.88% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $270.24 | +1.07% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $152.55 | +2.39% |
| Roche Holding AGSWX: ROP | $373.91B | CHF375.60 | +1.02% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £122.40 | +1.26% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.07 | +1.01% |
Figures last refreshed Aug 18, 2026.